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Abstract
Ezrin, ERK, STAT3, and AKT are proteins that are overexpressed in various types of
cancer, although their expressions in tongue cancer has received less focus. This study
aimed to address associations between the expression levels of these proteins and with
characteristics of the tumor and patient survival. We performed immunohistochemical
staining of ezrin, ERK, STAT3, and AKT in tumors from patients with tongue carcinoma
in situ (CIS, n = 17) and tongue squamous cell carcinoma (SCC, n = 46). Statistical differ-
ences between the SCC versus the CIS cohorts were estimated by calculations of
bivariate odds ratios of low versus high expression of the proteins. Fisher's exact tests
were used to appraise interassociations between the proteins, as well as expression
levels versus patient and tumor characteristics. Survival based on Kaplan–Meier statis-
tics in combination log-rank tests were used to address potential effects of the patient
and tumor characteristics versus 5-year survival rate. The relative high: low expression
of all four proteins in the two cohorts differed, and particularly ERK was markedly
overexpressed in the SCC versus the CIS cohort (odds ratio = 45.3, p < .01). The rela-
tive high: low expression each protein versus patient and tumor characteristics; showed
associations between AKT expression and T stage (p = .002) plus node metastases
(p = .12), and between ERK expression and drinking (p = .01) and smoking history
(p = .01). There was no significant difference observed between ERK and the three
other molecules, nor any significant difference between the degree of expression of
each protein and the 5-year disease-specific survival rate. Ezrin, ERK, STAT3, and AKT
appear to be involved in the progress from carcinoma in situ in the tongue into squa-
mous cell carcinoma. ERK in particular is overexpressed, suggesting that ERK may be a
novel therapeutic target for preventing tongue cancer.
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1 | INTRODUCTION
Oral tongue squamous cell carcinoma (OTSCC) accounts for approxi-
mately 1.5% of all cancer cases and is an aggressive cancer that is fre-
quently associated with a poor prognosis (Ganly, Patel, & Shah, 2012). In
Japan, the number of patients with oral cancer has been increasing annu-
ally. In oral cancer cases, the tongue is the most frequently observed site
of cancer development (Japan Society for Head and Neck Cancer Registry
Committee, 2003). It has been estimated that 6–7% cases of tongue can-
cer occur in patients aged <40 years (Garavello, Spreafico, & Gaini, 2007).
The tongue has a rich lymphatic network, which makes it the site that
is most frequently associated with cervical metastasis of cancer at other
sites in the oral cavity. The presence of nodal metastasis in the neck is the
most important prognostic factor. In addition, clinicopathological prognos-
tic factors, including TNM stage, grade, and the depth of tumor invasion,
are essential in predicting the course of disease and in the determination
of appropriate treatment methods. Despite considerable advances in diag-
nostic and therapeutic techniques, patients with OTSCC have a poor prog-
nosis, with an estimated 5-year overall survival rate of only 56%
(Bettendorf, Piffko, & Bankfalvi, 2004). We previously reported that ezrin
is overexpressed in OTSCC and plays a vital role in tongue cancer cell
growth, migration, and invasiveness via the E-cadherin/b-catenin complex
and cadherin switch (Saito et al., 2013).
Theocharis et al. have reported that ERK is overexpressed in
tongue cancer cells and infiltrating lymphoid cells and is correlated with
important clinicopathological parameters of patient management and
prognosis. Therefore, ERK expression and activation in tumor cells and
infiltrating lymphocytes is considered to be a useful prognostic marker
in tongue cancer (Theocharis et al., 2014). Moreover, Stat3 is involved
in the motility, metastasis, and progression in human lingual SCC (Zhao
et al., 2013). The activation of AKT is an important prognostic factor for
disease-free survival of patients with OTSCC regardless of the stage
and lymph node status and can be used as a predictive marker for sec-
ond primary tumors and recurrences (Massarelli et al., 2005).
Many studies have reported that ezrin, ERK, STAT3, and AKT are
associated with the development of tongue cancer cells and with the
prognosis of patients with OTSCC. However, for OTSCC, there are
few reports assessing the association between these molecules and
patient survival rate; moreover, the associations between ezrin, ERK,
STAT3, and AKT expressions and clinicopathological features have
been analyzed using the same sample.
The purpose of this study was to analyze the association between
the expression of each molecule and the survival rate of patients with
OTSCC, and the clinicopathological features of OTSCC using
immunohistological staining.
2 | MATERIALS AND METHODS
2.1 | Patients
This study included 63 patients who received treatment for OTSCC
from the Dental Oral Surgery or Otolaryngology departments at the
Shiga University of Medical Science Hospital between January 2005
and December 2014. Data regarding patient sex and age, tumor size/
extent, presence of regional lymph node metastases, distant metasta-
ses, and clinical stage were collected from medical records. Tumor
staging was performed according to the TNM classification of the
International Union Against Cancer. Histological differentiation was
defined according to the World Health Organization classification.
Before surgery, all patients underwent a physical examination, com-
puted tomography (CT), magnetic resonance imaging, and ultrasonog-
raphy and positron emission tomography/CT examination to examine
the primary tumor and cervical lymph nodes. Following primary partial
glossectomy with unilateral or bilateral cervical lymph node dissection,
the final histopathology report confirmed that all patients had negative
surgical margins. Formalin-fixed paraffin-embedded block specimens of
carcinoma in situ (CIS) (17 cases) and invasive SCC of the tongue
(46 cases), surgically removed at the Shiga University of Medical Sci-
ence Hospital, were examined in this study. This study was approved by
the Ethics Committee of the hospital (approval no. 27–78).
2.2 | Immunohistochemical staining
Sequential sections (3-μm thick) were prepared from the paraffin
blocks of maximum cut surface specimens for each case. These sam-
ples were immunohistochemically stained for ezrin, ERK, AKT, and
STAT3. The intensity of staining was classified on a 4-point scale: 0, 1
+, 2+, and 3+, with 0 and 1+ indicating low levels and 2+ and 3+ indi-
cating high levels. The degree of staining was compared between CIS
and SCC. The antibodies used were anti-ezrin rabbit antibody (1:100,
#3145; Cell Signaling, Danvers, MA), anti-p44/42 MAP kinase mouse
antibody (1:500, #4696; Cell Signaling), anti-AKT mouse antibody
(1:250, #2920; Cell Signaling), and anti-STAT3 mouse antibody
(1:600, #9139; Cell Signaling.
Immunostaining was performed using a Discovery XT Automated
IHC Stainer with a Ventana DABMap Detection kit (no. 760–124;
Ventana Medical System, Oro Valley, AZ). Each step of the Ventana
DABMap detection kit procedure was optimized for the Discovery XT
instrument; conditions including the dilutions of each antibody were
established before measurements. In all cases, the antigen was acti-
vated by heating.
2.3 | Statistical analysis
Descriptive statistics as used to describe characteristics of the sub-
jects in the SSC and CIS cohorts and subjected to chi-square statistics
to assess differences with regard to categorical demographic vari-
ables. Bivariate odds ratios were estimated on basis of low versus high
expression of respectively, ezrin, ERK, STAT 3, and AKT in the SCC
versus the CIS cohort. The high/low expressions of ERK versus high/
low expressions of ezrin, STAT 3 and AKT were appraised by use of
Fisher's exact test. The associations between the high/low expres-
sions of ezrin, ERK, STAT 3, and AKT versus patient and tumor
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characteristics were analyzed in the SCC cohort using Fisher's exact
test. Finally, the 5-year disease-specific survival (DSS) rate was calcu-
lated by using the Kaplan–Meier method. Log-rank tests were applied
to assess differences in survival rates as a function of high/low
expressions of the target molecules. p < .05 was considered to indi-
cate a statistically significant difference.
3 | RESULTS
3.1 | Patient characteristics
The clinical characteristics of patients and the comparison of CIS and
SCC are shown in Table 1. The mean age was 65.5 years (range,
33–86 years) for SCC cases and 67.6 years (range, 44–87 years) for
CIS cases. Among the SCC cases, T1 was the highest at 24 cases
(52.2%), and 11 cases (23.9%) showed lymph node metastasis. Histo-
logical differentiation was most common in 33 cases (71.8%) in Well.
In terms of smoking history, the proportion of SCC cases with or with-
out a smoking history was almost the same, whereas, more CUS cases
had a smoking history. In terms of drinking history, SCC and CIS cases
were more likely to be absent. There was no significant difference
between CIS and SCC for sex, smoking history, or drinking history.
3.2 | Comparison of the expression of each
molecule between CIS and SCC
Immunostaining was performed on CIS and SCC, and the degree of expres-
sion of the molecule was evaluated. The results are shown in Table 2.
In cases of high expression, ezrin expression was particularly high
in the cell membrane. Stat3 was expressed highly in the cytoplasm and
nucleus of cancer cells. ERK and AKT were mainly expressed in the
cytoplasm of cancer cells, whereas AKT was expressed at high levels in
the invasive front of tumor foci (Figure 1). The degrees ezrin, ERK, STAT
3, and AKT expressions were significant different between CIS and SCC
cases. It was suggested that the molecules evaluated in this study are
involved in the development of CIS to SCC in the tongue. Among them,
ERK exhibited a low correlation (OR = 45.3), which was present at low
levels in 16 cases and high levels in three cases for CIS, and low levels
in 12 cases and high levels in 34 cases for SCC.
ERK was followed by ezrin (OR = 18.1), AKT (OR = 17.5), and
STAT 3 (OR = 10.7), with minimal difference in correlation strength
between ezrin and AKT. Fisher's exact test revealed that ERK expres-
sion is likely to be associated with ezrin expression, but as with the
other molecules, no significant difference was observed (Table 3).
3.3 | Associations between the expression of each
molecule and tumor characteristics in SCC
The degree of expression of each protein was appraised relative to
patient and tumor characteristics in the SCC cohort (Table 4). For age,
sex, and histological differentiation, there was no significant differ-
ence for any molecule.
The degrees STAT3 and AKT expressions tended to increase as
the T stage progressed. Fisher's exact test revealed that AKT expres-
sion was likely to be associated with the T stage, with a significant dif-
ference observed (p < 0.05). Fisher's exact test showed that ERK
expression was likely to be associated with ezrin expression, but as
with the other molecules, no significant difference was observed. The
degrees of ezrin and AKT expressions tended to increase as node
metastases progressed. Fisher's exact test revealed that AKT expres-
sion was likely to be associated with node metastases, with a signifi-
cant difference observed (p < .05). Therefore, it was suggested that
TABLE 1 Patient and tumor characteristics of patients with
tongue carcinoma in situ (CIS) and tongue squamous cell
carcinoma (SCC)
Characteristics
SCC CIS
p-value(n = 46) (%) (n = 17) (%)
Age (years)
Range 33–86 44–87
Mean 65.5 67.6
Gender
Male 23 (50.0) 11 (64.7) .3962
Female 23 (50.0) 6 (35.3)
T stage
Tis — 17 (100)
T1 24 (52.2) —
T2 12 (26.1) —
T3 1 (2.1) —
T4 9 (19.6) —
Node metastases
No 35 (76.1) 17 (100)
Yes 11 (23.9) —
Clinical stage
Stage I 23 (50.0) —
Stage II 10 (21.8) —
Stage III 2 (4.3) —
Stage IV 11 (23.9) —
Histological differentiation
Well 33 (71.8) —
Moderate 12 (26.1) —
Poor 1 (2.1) —
Smoking history
No 25 (54.3) 7 (41.2) .4048
Yes 21 (45.7) 10 (58.8)
Drinking history
No 29 (63.0) 12 (70.6) .7673
Yes 17 (37.0) 5 (29.4)
Note: Chi-square statistics.
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AKT is associated with the growth and metastasis of tongue cancer
cells.
In terms of smoking history, the degree of ERK expression
tended to decrease as smoking history was reported, indicating that
ERK expression was likely to be associated with smoking history,
and a significant difference was observed (p < .05). Similarly, for
drinking history, ERK expression level tended to decrease as a drink-
ing history was recognized (p < .05). This suggested that ERK is
strongly related to smoking history and drinking history.
3.4 | Associations between the expression of each
molecule and the 5-year DSS
Univariate analysis using the log-rank test and the Kaplan–Meier
method demonstrated that ezrin and STAT3 expression levels, and AKT
were likely to be associated with 5-year DSS, but no significant differ-
ence was observed between cases with high levels and low levels.
TABLE 2 High versus low expression
of the proteins Ezrin, ERK, STAT 3, and
AKT in tongue cancerExpression of molecules
Ezrin ERK STAT3 AKT
Low High Low High Low High Low High
CIS (n = 17) 13 4 16 1 14 3 16 1
SCC (n = 46) 7 39 12 34 14 32 22 24
Odds ratio 18.1 45.3 10.7 17.5
p-value p < .01 p < .01 p < .01 p < .01
Note: Fischer exact test statistics.
F IGURE 1 Ezrin-, ERK-, STAT3-, and AKT-stained images of human tongue cancer tissue (scale bar: 100 μm). Brown color represents cells
positive for protein, as visualized by DAB staining
TABLE 3 High versus low expression of the ERK versus the
proteins Ezrin, STAT 3, and AKT in tongue cancer
Ezrin STAT3 AKT
Low High Low High Low High
ERK Low 4 8 5 7 8 4
High 3 31 9 25 14 20
p-value .06 .47 .18
Note: Fischer exact test statistics.
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By contrast, patients with low levels of ERK had a lower 5-year
DSS than those with high levels of ERK (Figure 2a).
Although the 5-year DDS was analyzed between the groups by
combining ezrin, ERK, STAT3, and AKT, no significant difference was
recognized between high levels and low levels (Figure 2b).
4 | DISCUSSION
The results of the present study suggest that ezrin, ERK, STAT 3, and
AKT are involved in the development from tongue CIS to tongue SCC,
that AKT is associated with T stage, and that ERK is associated with
alcohol and smoking habits. By contrast, the results indicated that
there was no significant difference between the molecules and the
5-year DSS, which was not associated with the survival rate.
Serine/threonine protein kinase AKT, an important target of the
phosphoinositide-3-kinase/AKT signaling pathway, is abnormally
activated in various types of tumor, including those in head and neck
cancer (Amornphimoltham et al., 2004) (including OTSCC) (Massarelli
et al., 2005).
AKT is able to phosphorylate and regulate a number of proteins
associated with cell metabolism, apoptosis, proliferation, and differen-
tiation, thereby inhibiting the apoptosis of tumor cells and promoting
the proliferation of tumor cells.
The activation of AKT is associated with the progression of squa-
mous epithelial cells from the normal epithelium to dysplasia, and then
to invasive carcinoma (Amornphimoltham et al., 2004); in the results
of the present study, AKT expression was also significantly high in
cases with an advanced T stage. It was confirmed that AKT was asso-
ciated with the progression of OTSCC.
OTSCC is associated with numerous factors, including age, geo-
graphical location, and family history. Tongue cancer is also associated
with habits including smoking and alcohol abuse. Although each is an
independent risk factor, these two factors may potentially synergize
TABLE 4 High versus low expression
of the proteins Ezrin, ERK, STAT 3, and
AKT in tongue cancer versus patient and
tumor characteristics of patients with
tongue squamous cell carcinoma (SCC
SCC characteristics
Ezrin ERK STAT3 AKT
Low High Low High Low High Low High
Age (years)
>65 6 26 8 24 6 26 11 21
≤65 4 19 6 17 9 14 11 12
p-value 1.000 1.000 .1282 .4055
Gender
Male 7 24 11 20 6 25 10 21
Female 3 21 3 21 9 15 12 12
p-value .4856 .0666 .2216 .2675
T stage
T1 + T2 6 34 9 31 13 27 21 19
T3 + T4 4 11 5 10 2 13 1 14
p-value .4339 .4926 .1923 .0019
Node metastases
No 5 34 8 31 12 27 19 20
Yes 5 11 6 10 3 13 2 14
p-value .1342 .3060 .5103 .0150
Histological differentiation
Well 9 33 8 34 12 30 16 26
Moderate/poor 1 12 6 7 3 10 6 7
p-value .4214 .0710 1.000 .7481
Smoking history
No 4 25 3 26 9 20 10 19
Yes 6 20 11 15 6 20 12 14
p-value .4901 .0118 .5578 .4196
Drinking history
No 3 29 4 28 8 24 13 19
Yes 7 16 10 13 7 16 9 14
p-value .0751 .0131 .7621 1.000
Note: Fischer exact test statistics.
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and increase the risk of developing cancer. In an epidemiological sur-
vey targeting Caucasian men, the relative risk of HNSCC was 34 times
higher for people who had these habits than for those without
tobacco and alcohol use, seven times higher for tobacco only, and
three times higher for alcohol only (Osei-Sarfo, Tang, Urvalek,
Scognamiglio, & Gudas, 2013).
The nicotine contained in tobacco activates ERK, promotes can-
cer cell proliferation and angiogenesis through the nicotinic acetylcho-
line receptor, and is involved in tumor growth, and the tongue
influenced by alcohol and tobacco is reported to have increased ERK
expression in vivo (Osei-Sarfo et al., 2013). However, our results
showed that ERK expression tended to be lower for cases with a posi-
tive smoking history and drinking history, contrary to the results of
previous reports. Although the factors remain unknown, the associa-
tions among smoking, alcohol, and ERK require further investigation
regarding OTSCC.
ERK is a downstream component of the signal module activated
by Raf serine/threonine kinase. In cancer, the ERK/MAPK signal is
abnormally activated by the upstream activation by epidermal growth
factor receptor (epidermal growth factor receptor) and Ras GTPases
(small guanosine triphosphatase), and it is involved in promoting can-
cer cell proliferation, survival, and metastasis (Roberts & Der, 2007).
The ERK expression is reported to cause resistance to radiation ther-
apy and chemotherapy in malignant melanoma (Smalley, 2003).
The inhibition of ERK signaling inhibits tumor growth in various
types of cancer, including gastric cancer (Wu et al., 2013), renal cell
carcinoma (Fang et al., 2013), and rhabdomyosarcoma (Renshaw et al.,
2013). We have also revealed that the activation of ERK in tongue
cancer cell lines cultured three-dimensionally using silica fiber is asso-
ciated with the formation of invadopodia (Noi et al., 2018).
However, ERK has not been reported to be associated with sur-
vival in patients with prostate cancer (Han et al., 2017), and even in
the present study, although the 5-year DSS was high in cases with
high levels of ERK compared with those with low levels, there was no
significant difference between them.
Ezrin expression in breast cancer (Wang et al., 2009), endometrial
cancer (Ohtani et al., 1999), uterine cancer (Kobel et al., 2006), uveal
melanoma (Ilmonen, Vaheri, Asko-Seljavaara, & Carpen, 2005), and
soft tissue sarcoma (Weng, Ahlén, Aström, Lui, & Larsson, 2005) is
associated with low survival rate. STAT3 has been reported to be
associated with the survival rate of patients with nonsmall cell lung
cancer (Sun et al., 2018) and AKT has been associated with survival
rate in esophageal cancer (Shan, Chen, Wang, Wang, & Fan, 2017).
However, in the present study, as with ERK, there was no significant
F IGURE 2 Kaplan–Meier 5-year disease-specific survival (DSS) rate evaluated according to the expression levels of Ezrin, ERK, STAT3, and
AKT. (a) There was no significant difference between high levels and low levels of various proteins. For ERK, a high level had a higher 5-year DSS
rate than a low level. (b) There were no significant differences between the high and low levels of the various proteins
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difference between ezrin, STAT3, or AKT and 5-year DSS. Therefore,
it was suggested that these molecules are not associated with survival
in OTSCC. It has been reported that ERK serves an important role in
the preinvasive stage of oral epithelial tumors (Degen, Natarajan,
Barron, Widlund, & Rheinwald, 2012); compared with the association
of molecules including ezrin, STAT3, and AKT and the development
from tongue CIS to OTSCC, ERK was found to have the highest corre-
lation (OR = 45.3), consistent with previous reports.
There are been various reports on the association between
ERK and ezrin. For example, Ezrin-mediated early metastatic sur-
vival was partially dependent on the activation of MAPK, but not
AKT in osteosarcoma (Khanna et al., 2004). In addition, the phos-
phorylation of ERK was reduced in ezrin-KD cells, and activation
of the ERK/MAPK pathway may partially attenuate the Ezrin-
mediated suppression of cell invasiveness in esophageal SCC (Xie
et al., 2009). In addition, the inhibition of ezrin reduces the interac-
tion with EGFR and reduces the level of phosphorylation of ERK
and STAT3, which are downstream target genes of EGFR
(Saygideger-Kont et al., 2016).
In terms of the relationship between AKT and ERK, there are
reports that AKT can inhibit ERK signaling and cause a shift in can-
cer cellular responses from cell cycle arrest to proliferation
(Zimmermann & Moelling, 1999), and that ERK and AKT pathways
can collaborate to maintain cell viability (Dent, 2014). However, the
exact intersects between ERK and ezrin, AKT, and STAT3 are not
fully understood. In the present study, no significant difference was
observed following comparison of the degree of the expression of
ERK and other molecules in the same specimen.
Currently, with the evidence that ERK signaling is involved in cell
proliferation, cell survival, and metastasis, numerous laboratories have
focused on the development of ERK inhibitors for cancer treatment
(Roberts & Der, 2007). In the future, ERK may be a target for preven-
tion and control of the progress of OTSCC.
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